124 related articles for article (PubMed ID: 9339643)
21. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
[TBL] [Abstract][Full Text] [Related]
22. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
23. Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004.
Fayette J; Blay JY
Curr Opin Oncol; 2005 Jul; 17(4):370-5. PubMed ID: 15933471
[TBL] [Abstract][Full Text] [Related]
24. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.
Izquierdo MA; Shoemaker RH; Flens MJ; Scheffer GL; Wu L; Prather TR; Scheper RJ
Int J Cancer; 1996 Jan; 65(2):230-7. PubMed ID: 8567122
[TBL] [Abstract][Full Text] [Related]
25. ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas.
Oda Y; Saito T; Tateishi N; Ohishi Y; Tamiya S; Yamamoto H; Yokoyama R; Uchiumi T; Iwamoto Y; Kuwano M; Tsuneyoshi M
Int J Cancer; 2005 May; 114(6):854-62. PubMed ID: 15609299
[TBL] [Abstract][Full Text] [Related]
26. [Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].
Katsaros D; Fracchioli S; Arts HJ; de Vries EG; Danese S; Richiardi G; Arisio R; Gordini G; Van der Zee AG; Suurmeijer AJ; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):463-70. PubMed ID: 10767994
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer.
Sedláková I; Laco J; Caltová K; Červinka M; Tošner J; Řezáč A; Špaček J
Int J Gynecol Cancer; 2015 Feb; 25(2):236-43. PubMed ID: 25594141
[TBL] [Abstract][Full Text] [Related]
28. [The expression of multiple drug resistance associated genes in ovarian cancer].
Cheng G; Zhu H; Sun L
Zhonghua Fu Chan Ke Za Zhi; 2000 Feb; 35(2):87-90. PubMed ID: 11809106
[TBL] [Abstract][Full Text] [Related]
29. Expression of lung resistance protein in epithelioid sarcoma in vitro and in vivo.
Kusakabe H; Iwasaki H; Sano K; Kiyokane K
Arch Dermatol Res; 2000 Jun; 292(6):292-300. PubMed ID: 10929770
[TBL] [Abstract][Full Text] [Related]
30. [Proteins of resistance and drug resistance in ovarian carcinoma patients].
Sedláková I; Laco J; Tošner J; Caltová K; Cervinka M; Rezáč A; Spaček J; Skapinec P
Klin Onkol; 2012; 25(6):457-63. PubMed ID: 23301649
[TBL] [Abstract][Full Text] [Related]
31. Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening.
Boven E; Pinedo HM; van Hattum AH; Scheffer PG; Peters WH; Erkelens CA; Schlüper HM; Kuiper CM; van Ark-Otte J; Giaccone G
Br J Cancer; 1998 Dec; 78(12):1586-93. PubMed ID: 9862568
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities.
Serra M; Scotlandi K; Manara MC; Maurici D; Benini S; Sarti M; Nini G; Barbanti-Brodano G; Baldini N
Cytotechnology; 1996; 19(3):253-6. PubMed ID: 8862015
[TBL] [Abstract][Full Text] [Related]
33. Disruption of P-glycoprotein anticancer drug efflux activity by a small recombinant single-chain Fv antibody fragment targeted to an extracellular epitope.
Haus-Cohen M; Assaraf YG; Binyamin L; Benhar I; Reiter Y
Int J Cancer; 2004 May; 109(5):750-8. PubMed ID: 14999785
[TBL] [Abstract][Full Text] [Related]
34. [Drug resistance proteins LRP, Pgp, MRP1, MRP3 and MRP5 in ovarian cancer patients].
Sedláková I; Laco J; Tošner J; Spaček J; Cermáková E
Ceska Gynekol; 2013 Dec; 78(6):545-53. PubMed ID: 24372433
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
36. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
37. Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients.
Stein U; Jürchott K; Schläfke M; Hohenberger P
J Clin Oncol; 2002 Aug; 20(15):3282-92. PubMed ID: 12149303
[TBL] [Abstract][Full Text] [Related]
38. Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line.
Hua J; Mutch DG; Herzog TJ
Gynecol Oncol; 2005 Jul; 98(1):31-8. PubMed ID: 15921732
[TBL] [Abstract][Full Text] [Related]
39. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
Naniwa J; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2007; 17(1):76-82. PubMed ID: 17291235
[TBL] [Abstract][Full Text] [Related]
40. Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
Susa M; Choy E; Yang C; Schwab J; Mankin H; Hornicek F; Duan Z
J Biomol Screen; 2010 Mar; 15(3):287-96. PubMed ID: 20150589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
